PE20141039A1 - Derivados glucosidos y usos de los mismos - Google Patents
Derivados glucosidos y usos de los mismosInfo
- Publication number
- PE20141039A1 PE20141039A1 PE2013002300A PE2013002300A PE20141039A1 PE 20141039 A1 PE20141039 A1 PE 20141039A1 PE 2013002300 A PE2013002300 A PE 2013002300A PE 2013002300 A PE2013002300 A PE 2013002300A PE 20141039 A1 PE20141039 A1 PE 20141039A1
- Authority
- PE
- Peru
- Prior art keywords
- 6alkyl
- halo
- hydroxyl
- compounds
- amino
- Prior art date
Links
- 229930182478 glucoside Natural products 0.000 title 1
- 150000008131 glucosides Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical class [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 abstract 1
- 229930182831 D-valine Natural products 0.000 abstract 1
- 208000008960 Diabetic foot Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE: A ES a), b) ENTRE OTROS, DONDE R2 Y R2a EN CADA CASO SE SELECCIONA DE HALO, HIDROXILO, C1-6 ALQUILO Y C1-6ALCOXILO; n ES 0,1,2, O 3 Y q ES 0,1 O 2; V ES H, HALO, U OR1b; R1, R1a Y R1b SON INDEPENDIENTEMENTE H, C1-6ALQUILO, C(O) C1-6ALQUILO, ENTRE OTROS; R3 ES HALO, HIDROXILO, C1-6ALQUILO, C1-6ALCOXILO, ENTRE OTROS; R4 ES c), d), ENTRE OTROS, DONDE R5 ES UNA CADENA LATERAL DE AMINOACIDOS Y R6 ES C1-6ALQUILO, C3-10CICLOALQUILO, C6-10ARILO, ENTRE OTROS. UN COMPUESTO PREFERIDO ES: ESTER (2R,3S,4R,5R,6S,)-6-[3-(2,3-DIHIDRO-BENZO[1,4]DIOXIN-6-ILMETIL)-4-ETIL-FENIL]-3,4,5-TRIHIDROXI-TETRAHIDRO-PIRAN-2-ILMETILICO DEL ACIDO (R)-2-AMINO-3-METIL-BUTIRICO, ENTRE OTROS. REFERIDO ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTO SON UTILES PARA EL TRATAMIENTO DE LA RETINOPATIA, PIE DIABETICO, HIPERTENSION, NEFROPATIA, ATEROSCLEROSIS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161475476P | 2011-04-14 | 2011-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20141039A1 true PE20141039A1 (es) | 2014-08-30 |
Family
ID=46028035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013002300A PE20141039A1 (es) | 2011-04-14 | 2012-04-12 | Derivados glucosidos y usos de los mismos |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8614195B2 (es) |
| EP (1) | EP2697217B1 (es) |
| JP (1) | JP5908973B2 (es) |
| KR (1) | KR20140027250A (es) |
| CN (1) | CN103748090B (es) |
| AP (1) | AP2013007179A0 (es) |
| AR (1) | AR086086A1 (es) |
| AU (1) | AU2012241427B2 (es) |
| BR (1) | BR112013026257A2 (es) |
| CA (1) | CA2832958A1 (es) |
| CL (1) | CL2013002973A1 (es) |
| CO (1) | CO6781541A2 (es) |
| CR (1) | CR20130530A (es) |
| CU (1) | CU20130139A7 (es) |
| EA (1) | EA201391525A1 (es) |
| ES (1) | ES2621007T3 (es) |
| IL (1) | IL228771A0 (es) |
| MA (1) | MA35032B1 (es) |
| MX (1) | MX2013011927A (es) |
| PE (1) | PE20141039A1 (es) |
| SG (1) | SG194463A1 (es) |
| TN (1) | TN2013000413A1 (es) |
| TW (1) | TW201245219A (es) |
| UY (1) | UY34018A (es) |
| WO (1) | WO2012140597A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2719656T3 (es) * | 2011-06-01 | 2019-07-11 | Green Cross Corp | Derivados de difenilmetano novedosos como inhibidores del SGLT2 |
| EP4245765A3 (en) | 2013-04-04 | 2024-03-20 | Boehringer Ingelheim Vetmedica GmbH | Treatment of metabolic disorders in equine animals |
| CN105518014B (zh) * | 2013-09-09 | 2018-03-23 | 上海研健新药研发有限公司 | C‑芳基葡糖苷衍生物、其制备方法及其在医药上的应用 |
| US9394329B2 (en) | 2013-09-27 | 2016-07-19 | Sunshine Lake Pharma Co., Ltd. | Glucopyranosyl derivatives and their uses in medicine |
| DK3082829T3 (da) | 2013-12-17 | 2021-05-03 | Boehringer Ingelheim Vetmedica Gmbh | Sglt2-inhibitorer til behandlingen af metaboliske lidelser i kattedyr |
| DK3096765T3 (en) | 2014-01-23 | 2019-03-04 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in dogs |
| ES2811261T3 (es) | 2014-04-01 | 2021-03-11 | Boehringer Ingelheim Vetmedica Gmbh | Tratamiento de trastornos metabólicos en animales equinos |
| WO2016046150A1 (en) | 2014-09-25 | 2016-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
| AU2016310535B2 (en) | 2015-08-27 | 2021-08-19 | Boehringer Ingelheim Vetmedica Gmbh | Liquid pharmaceutical compositions comprising SGLT-2 inhibitors |
| CN105294624B (zh) * | 2015-11-16 | 2018-01-12 | 山东罗欣药业集团股份有限公司 | 一种达格列净的制备方法 |
| CN108203432B (zh) * | 2016-12-20 | 2021-03-02 | 宜昌东阳光长江药业股份有限公司 | 吡喃葡萄糖基衍生物及其在医药上的应用 |
| US10952989B2 (en) | 2017-03-03 | 2021-03-23 | Novartis Ag | SGLT1/2 inhibitor LIK066 for treating obesity |
| WO2020242253A1 (ko) * | 2019-05-30 | 2020-12-03 | 동아에스티 주식회사 | Sglt-2 억제제인 신규 엠파글리플로진 유도체 |
| WO2021121270A1 (zh) * | 2019-12-19 | 2021-06-24 | 上海研健新药研发有限公司 | 一种SGLTs抑制剂的纯化方法及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1020944C (zh) | 1990-01-30 | 1993-05-26 | 阿图尔-费希尔股份公司费希尔厂 | 紧固件 |
| RU2232767C2 (ru) | 1999-08-31 | 2004-07-20 | Киссеи Фармасьютикал Ко., Лтд. | Глюкопиранозилоксипиразольные производные, фармацевтические композиции, содержащие эти производные, и промежуточные соединения для их получения |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| US6627611B2 (en) * | 2000-02-02 | 2003-09-30 | Kotobuki Pharmaceutical Co Ltd | C-glycosides and preparation of thereof as antidiabetic agents |
| TR200202200T2 (tr) | 2000-03-17 | 2002-12-23 | Kissei Pharmaceutical Co., Ltd. | Glükopiranosiloksibenzilbenzen türevleri, bu türevleri ihtiva eden tıbbi bileşimler ve türevlerin hazırlanması için ara-maddeler. |
| US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
| EA005994B1 (ru) | 2000-09-29 | 2005-08-25 | Киссеи Фармасьютикал Ко., Лтд. | Производные глюкопиранозилоксибензилбензола и содержащие их лекарственные композиции |
| US6936590B2 (en) | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| WO2003020737A1 (en) | 2001-09-05 | 2003-03-13 | Bristol-Myers Squibb Company | O-pyrazole glucoside sglt2 inhibitors and method of use |
| TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| JP2004137245A (ja) | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| TWI310033B (en) * | 2003-03-14 | 2009-05-21 | Yamanouchi Pharma Co Ltd | C-glycoside derivatives or salts thereof |
| AU2003902263A0 (en) | 2003-05-12 | 2003-05-29 | Fujisawa Pharmaceutical Co., Ltd. | Monosaccharide compounds |
| RU2374241C2 (ru) | 2003-05-20 | 2009-11-27 | Новартис Аг | N-ацилированные азотсодержащие гетероциклические соединения в качестве лигандов ppar-рецепторов, активируемых пролифератором пероксисомы |
| RS20060320A (en) | 2003-08-01 | 2008-08-07 | Janssen Pharmaceutica N.V., | Substituted indazole-o-glucosides |
| ATE422204T1 (de) | 2003-08-26 | 2009-02-15 | Boehringer Ingelheim Int | Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| AU2005219779B2 (en) | 2004-03-04 | 2011-04-14 | Kissei Pharmaceutical Co., Ltd. | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
| WO2005085265A1 (ja) | 2004-03-04 | 2005-09-15 | Kissei Pharmaceutical Co., Ltd. | 縮合ヘテロ環誘導体、それを含有する医薬組成物およびその医薬用途 |
| DE102004028241B4 (de) * | 2004-06-11 | 2007-09-13 | Sanofi-Aventis Deutschland Gmbh | Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel |
| US7393836B2 (en) | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
| DE102004034690A1 (de) | 2004-07-17 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| CA2574451A1 (en) | 2004-07-27 | 2006-02-02 | Boehringer Ingelheim International Gmbh | D-glucopyranosyl phenyl-substituted cyclene, medicaments containing these compounds, their use, and method for the production thereof |
| WO2006018150A1 (de) | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| DE102004048388A1 (de) | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| CA2588963C (en) | 2004-11-18 | 2013-06-25 | Kissei Pharmaceutical Co., Ltd. | 1-substituted-3-.beta.-d-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same |
| AR053329A1 (es) * | 2005-01-31 | 2007-05-02 | Tanabe Seiyaku Co | Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt) |
| US20080027014A1 (en) | 2006-07-28 | 2008-01-31 | Tanabe Seiyaku Co., Ltd. | Novel SGLT inhibitors |
| TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
| TW201000494A (en) * | 2008-02-13 | 2010-01-01 | Sanofi Aventis | Novel aromatic fluoroglycoside derivatives, medicaments comprising these compounds and use thereof |
| WO2010128152A1 (en) * | 2009-05-07 | 2010-11-11 | Novartis Ag | Fused heterocyclic c-glycosides for the treatment of diabetes |
| US8163704B2 (en) * | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
-
2012
- 2012-04-04 US US13/439,155 patent/US8614195B2/en active Active
- 2012-04-12 UY UY0001034018A patent/UY34018A/es not_active Application Discontinuation
- 2012-04-12 SG SG2013075908A patent/SG194463A1/en unknown
- 2012-04-12 ES ES12719083.3T patent/ES2621007T3/es active Active
- 2012-04-12 MA MA36319A patent/MA35032B1/fr unknown
- 2012-04-12 BR BR112013026257A patent/BR112013026257A2/pt not_active IP Right Cessation
- 2012-04-12 AP AP2010307179A patent/AP2013007179A0/xx unknown
- 2012-04-12 AU AU2012241427A patent/AU2012241427B2/en not_active Ceased
- 2012-04-12 CA CA2832958A patent/CA2832958A1/en not_active Abandoned
- 2012-04-12 PE PE2013002300A patent/PE20141039A1/es not_active Application Discontinuation
- 2012-04-12 EA EA201391525A patent/EA201391525A1/ru unknown
- 2012-04-12 JP JP2014504432A patent/JP5908973B2/ja not_active Expired - Fee Related
- 2012-04-12 WO PCT/IB2012/051799 patent/WO2012140597A1/en active Application Filing
- 2012-04-12 KR KR1020137029813A patent/KR20140027250A/ko not_active Application Discontinuation
- 2012-04-12 MX MX2013011927A patent/MX2013011927A/es not_active Application Discontinuation
- 2012-04-12 EP EP12719083.3A patent/EP2697217B1/en active Active
- 2012-04-12 CN CN201280028536.3A patent/CN103748090B/zh not_active Expired - Fee Related
- 2012-04-13 AR ARP120101273A patent/AR086086A1/es unknown
- 2012-04-13 TW TW101113290A patent/TW201245219A/zh unknown
- 2012-09-13 US US13/613,090 patent/US20130018005A1/en not_active Abandoned
-
2013
- 2013-10-07 IL IL228771A patent/IL228771A0/en unknown
- 2013-10-10 CO CO13241013A patent/CO6781541A2/es not_active Application Discontinuation
- 2013-10-11 TN TNP2013000413A patent/TN2013000413A1/fr unknown
- 2013-10-14 CU CU2013000139A patent/CU20130139A7/es unknown
- 2013-10-14 CR CR20130530A patent/CR20130530A/es unknown
- 2013-10-14 CL CL2013002973A patent/CL2013002973A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5908973B2 (ja) | 2016-04-26 |
| TN2013000413A1 (en) | 2015-03-30 |
| MA35032B1 (fr) | 2014-04-03 |
| CA2832958A1 (en) | 2012-10-18 |
| JP2014511874A (ja) | 2014-05-19 |
| WO2012140597A1 (en) | 2012-10-18 |
| SG194463A1 (en) | 2013-12-30 |
| BR112013026257A2 (pt) | 2019-09-24 |
| US20120264700A1 (en) | 2012-10-18 |
| CU20130139A7 (es) | 2014-01-29 |
| IL228771A0 (en) | 2013-12-31 |
| AU2012241427B2 (en) | 2014-11-20 |
| US20130018005A1 (en) | 2013-01-17 |
| CL2013002973A1 (es) | 2014-03-07 |
| US8614195B2 (en) | 2013-12-24 |
| AR086086A1 (es) | 2013-11-20 |
| CN103748090B (zh) | 2016-09-14 |
| ES2621007T3 (es) | 2017-06-30 |
| EP2697217A1 (en) | 2014-02-19 |
| CO6781541A2 (es) | 2013-10-31 |
| CN103748090A (zh) | 2014-04-23 |
| AP2013007179A0 (en) | 2013-10-31 |
| UY34018A (es) | 2012-11-30 |
| TW201245219A (en) | 2012-11-16 |
| CR20130530A (es) | 2014-02-04 |
| MX2013011927A (es) | 2013-11-01 |
| KR20140027250A (ko) | 2014-03-06 |
| AU2012241427A1 (en) | 2013-10-31 |
| EP2697217B1 (en) | 2016-12-28 |
| EA201391525A1 (ru) | 2014-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20141039A1 (es) | Derivados glucosidos y usos de los mismos | |
| BR112013011580A2 (pt) | derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep | |
| AR079022A1 (es) | Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion | |
| BR112014015363A2 (pt) | derivados de ácido alfa-amino borônico, inibidores de imunoproteassoma seletivos | |
| EA201200763A1 (ru) | Замещенные производные карбамоилметиламиноуксусной кислоты в качестве новых ингибиторов nep | |
| AR073138A1 (es) | Derivados de dioxa-biciclo (3.2.1) octano- 2,3,4-triol | |
| CU20110216A7 (es) | Derivados aminobutíricos sustituidos como inhibidores de neprilisina | |
| PE20211290A1 (es) | Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad del parkinson | |
| CO6170361A2 (es) | Composiciones y metodos para modular receptores de c-kit y pdgfr | |
| ECSP088891A (es) | Derivados bicíclicos como inhibidores de cetp | |
| PE20150194A1 (es) | Novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa | |
| EA201101671A1 (ru) | Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина | |
| PE20142456A1 (es) | COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks | |
| GT201300091A (es) | Compuestos de furo (3,2-d) pirimidina | |
| PE20141205A1 (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2 | |
| ECSP088099A (es) | Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas | |
| PE20140976A1 (es) | Inhibidores de benzodioxano de la producion de leucotrieno | |
| PE20151006A1 (es) | Derivados de oxazolidin-2-ona-pirimidina | |
| PE20141204A1 (es) | Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa | |
| PE20142450A1 (es) | Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1 | |
| EA201070483A1 (ru) | Новые офтальмологические композиции | |
| AR050914A1 (es) | Agonista receptor de vasopresina peptidico | |
| BR112013000248A2 (pt) | derivados de dióxido de 1,3-propano espirociclicamente substituído, método para a produção dos mesmos e uso dos mesmos como medicamento | |
| PE20151666A1 (es) | Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep | |
| AR084781A1 (es) | Composiciones que comprenden y metodos que utilizan inhibidores de los cotransportadores de sodio-glucosa 1 y 2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |